Search results
Lilly’s Weight-Loss Drug Is a Huge Hit. Its CEO Wants to Replace It ASAP.
The Wall Street Journal· 11 hours agoAnd we’re investing heavily in that.” Last year, Lilly acquired a company developing a drug designed...
Eli Lilly exec on weight-loss drugs: 'It's not just a flash in the pan'
Yahoo Finance via AOL· 4 days agoEli Lilly may be riding high on its diabetes and weight-loss treatments Mounjaro and Zepbound —...
GLP-1 Discontinuation Less Common With Endocrinologists
Medscape· 4 days agoPatients taking glucagon-like peptide 1 (GLP-1) receptor agonists for obesity appear to be...
More People — Including Children — Are Being Intentionally Poisoned in the U.S.
People via Yahoo News· 3 days agoGetty Stock image of pills on a counter. And while there was an overall decrease in...
Structure Therapeutics (GPCR) Rallying on Obesity Drug Data
Zacks via Yahoo Finance· 3 days agoStructure Therapeutics (GPCR) stock sees an upside on positive top-line data from a phase IIa...
Small Business - Picayune Item | Picayune Item
The Picayune Item· 6 days agoEli Lilly and Company (NYSE: LLY) announced detailed results from SYNERGY-NASH, a phase 2 study of 190 patients, with or without type 2 diabetes, to evaluate the investigational ...
Here’s Why Viking Therapeutics (VKTX) Shares Rose in Q1
Insider Monkey via Yahoo Finance· 3 days agoBaron Funds, an investment management company, released its “Baron Opportunity Fund” first quarter...